{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:03:37Z","timestamp":1766995417602,"version":"3.48.0"},"reference-count":30,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sir Harold Cuthbertson Foundation"},{"name":"Select Foundation Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Prostate cancer (PrCa) outcomes are inferior in regional and rural areas compared to metropolitan centres. We evaluated patterns of care in PrCa patients treated in public and private healthcare facilities in regional Tasmania. Methods: This retrospective study used clinicopathological data for 2180 PrCa patients diagnosed between 2015\u20132022. Descriptive statistics and regression analyses determined associations between treatment facility (public vs. private) and diagnostic and treatment factors. Results: A significantly greater proportion of public patients were from outer regional\/remote areas (prevalence ratio (PR) = 1.25, 95% CI: 1.19\u20131.31), presented with higher-risk disease (PR = 1.56, 95% CI: 1.22\u20132.00) and underwent active treatment compared to private patients (PR = 1.07, 95% CI: 1.03\u20131.11). Men treated privately were most likely to have low-risk PrCa (p &lt; 0.001) and be managed with active surveillance (AS, 52.9%). When stratified by disease risk, public patients with intermediate (p &lt; 0.001) or very high-risk\/metastatic disease (p = 0.003) were still significantly more likely to receive active treatment than private patients. Furthermore, except for very high-risk\/metastatic patients, public patients took significantly longer to commence treatment, ranging between a mean difference of 40 to 59 days depending on risk category. Conclusions: In Tasmania, treatment pathways for PrCa patients differ significantly between public and private healthcare sectors and may contribute to poorer outcomes in regional and remote areas.<\/jats:p>","DOI":"10.3390\/cancers18010079","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:52:59Z","timestamp":1766994779000},"page":"79","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate Cancer Disparities Between Public and Private Healthcare Patients in Tasmania, a Regional State of Australia"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2548-0093","authenticated-orcid":false,"given":"Georgea R.","family":"Foley","sequence":"first","affiliation":[{"name":"Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7001, Australia"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Leigh","family":"Blizzard","sequence":"additional","affiliation":[{"name":"Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7001, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marketa","family":"Skala","sequence":"additional","affiliation":[{"name":"WP Holman Clinic, Royal Hobart Hospital, Hobart, TAS 7000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Redwig","sequence":"additional","affiliation":[{"name":"Urology Department, Royal Hobart Hospital, Hobart, TAS 7000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Roydhouse","sequence":"additional","affiliation":[{"name":"Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7001, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne L.","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7001, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6882-2698","authenticated-orcid":false,"given":"Liesel M.","family":"FitzGerald","sequence":"additional","affiliation":[{"name":"Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7001, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.eururo.2017.06.035","article-title":"Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review","volume":"72","author":"Lardas","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2025.05.014","article-title":"Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data","volume":"89","author":"Li","year":"2026","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","article-title":"Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review","volume":"77","author":"Moris","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/jama.2024.20580","article-title":"Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010\u20132020","volume":"332","author":"Ajjawi","year":"2024","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ucl.2025.09.009","article-title":"Active Surveillance for Prostate Cancer","volume":"53","author":"Klotz","year":"2026","journal-title":"Urol. Clin. N. Am."},{"key":"ref_6","first-page":"1032","article-title":"The interplay and influence of anxiety and depression among men with early-stage prostate cancer and their close allies","volume":"33","author":"Majumdar","year":"2025","journal-title":"Support. Care Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5694\/mja2.50794","article-title":"Differences in treatment choices for localised prostate cancer diagnosed in private and public health services","volume":"213","author":"Milne","year":"2020","journal-title":"Med. J. Aust."},{"key":"ref_8","unstructured":"Australian Institute of Health and Welfare (2025, November 01). Cancer Data in Australia, Available online: https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/contents\/state-and-territory."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41598-022-06958-2","article-title":"Urban-rural prostate cancer disparities in a regional state of Australia","volume":"12","author":"Foley","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bju.13258","article-title":"Development of an International Prostate Cancer Outcomes Registry","volume":"117","author":"Evans","year":"2016","journal-title":"BJU Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.6004\/jnccn.2010.0012","article-title":"NCCN clinical practice guidelines in oncology: Prostate cancer","volume":"8","author":"Mohler","year":"2010","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00345-016-1985-1","article-title":"Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis","volume":"35","author":"Pepdjonovic","year":"2017","journal-title":"World J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41391-020-0205-7","article-title":"A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI-US fusion biopsy for prostate-cancer detection","volume":"23","author":"Ber","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0090-4295(02)02551-7","article-title":"Best approach for prostate cancer detection: A prospective study on transperineal versus transrectal six-core prostate biopsy","volume":"61","author":"Emiliozzi","year":"2003","journal-title":"Urology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000003788","article-title":"Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial","volume":"211","author":"Mian","year":"2024","journal-title":"J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.euo.2024.01.019","article-title":"Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1)","volume":"7","author":"Ploussard","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial","volume":"86","author":"Hu","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/JU.0000000000003979","article-title":"Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial","volume":"212","author":"Mian","year":"2024","journal-title":"J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.5694\/mja12.11241","article-title":"Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011","volume":"198","author":"Evans","year":"2013","journal-title":"Med. J. Aust."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/ans.14722","article-title":"Patterns of care and outcomes for men diagnosed with prostate cancer in Victoria: An update","volume":"88","author":"Wang","year":"2018","journal-title":"ANZ J. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5694\/mja2.50966","article-title":"Patterns of care for men with prostate cancer: The 45 and Up Study","volume":"214","author":"Yap","year":"2021","journal-title":"Med. J. Aust."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e781\u2013786","DOI":"10.1016\/j.ijrobp.2011.11.024","article-title":"Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007","volume":"82","author":"Dinan","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1743-7563.2009.01237.x","article-title":"Clinical and socio-demographic profile of an Australian multi-institutional prostate cancer cohort","volume":"5","author":"Beckmann","year":"2009","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/pon.5255","article-title":"Ten-year quality of life outcomes in men with prostate cancer","volume":"29","author":"Ralph","year":"2020","journal-title":"Psycho-Oncology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"m3503","DOI":"10.1136\/bmj.m3503","article-title":"Fifteen year quality of life outcomes in men with localised prostate cancer: Population based Australian prospective study","volume":"371","author":"Mazariego","year":"2020","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1209978","article-title":"Long-term functional outcomes after treatment for localized prostate cancer","volume":"368","author":"Resnick","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1470-2045(11)70162-0","article-title":"Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: The Scandinavian Prostate Cancer Group-4 randomised trial","volume":"12","author":"Johansson","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejca.2016.05.020","article-title":"Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study","volume":"63","author":"Kerleau","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/bjc.2011.552","article-title":"Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer","volume":"106","author":"King","year":"2012","journal-title":"Br. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/79\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:59:40Z","timestamp":1766995180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18010079"],"URL":"https:\/\/doi.org\/10.3390\/cancers18010079","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]}}}